Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Novo Nordisk
Deal Size : $2,675.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Novo Nordisk will receive an exclusive, worldwide licence to use Aspect’s bioprinting technology to develop bioprinted tissue therapeutics including up to four products for the treatment of diabetes and obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $75.0 million
December 04, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Novo Nordisk
Deal Size : $2,675.0 million
Deal Type : Collaboration
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Lannett Company, Inc.
Deal Size : Undisclosed
Deal Type : Collaboration
Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin
Details : The biosimilar insulin aspart is currently in development and Lannett will help manage the remaining clinical and regulatory steps specific for a U.S. Food and Drug Administration (FDA) approval to market the product.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Undisclosed
September 02, 2021
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Lannett Company, Inc.
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes
Details : The expansion of our ZT-01 development program is based on promising results in a preclinical model of T2D and represents the potential to benefit a substantially larger population.
Product Name : ZT-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2020
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable